Assessment of FDA and EMA approved systemic oncology therapies and clinically meaningful improvements in quality of life

11 February 2021 - Are oncology therapies recently approved by the US FDA and the EMA associated with clinically meaningful improvements ...

Read more →

Explaining health state utility assessment

17 March 2020 - Health state utilities are used to provide quantitative measures of how strongly a person values a certain ...

Read more →

Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology

1 October 2018 - Progression-free survival has become a commonly used outcome to assess the efficacy of new cancer drugs. However, ...

Read more →

The “utility” in composite outcome measures

14 November 2017 - Measuring what is important to patients. ...

Read more →

Quality of life: an important element of treatment value

9 November 2017 - In the era of platinum-based chemotherapy, attempts to improve the quality of life of patients with advanced ...

Read more →

Quality of life, overall survival and costs of cancer drugs approved based on surrogate outcomes

14 February 2017 - The lack of evidence of a clinically meaningful benefit for many cancer drugs approved by the US ...

Read more →

Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints

29 November 2016 - The lack of evidence of a clinically meaningful benefit for many cancer drugs approved by the US ...

Read more →